New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in